Table 1 Baseline clinic characteristics of study participants (mITT Population)
Characteristic | CNIC-Polypill (N = 218) | Usual care (N = 221) |
|---|---|---|
Age (years), mean (SD) | 65.4 (8.6) | 64.1 (9.2) |
Sex (male), n (%) | 124 (56.9) | 138 (62.4) |
BMI (kg/m2), mean (SD) | 30.8 (5.1) | 30.5 (4.6) |
Medical history | ||
Current smoker, n (%) | 26 (11.9) | 33 (14.9) |
Years of smoking, mean (SD) | 36.7 (15,3) | 41.0 (12.3) |
Cigarettes per day, mean (SD) | 13.0 (9.2) | 19.3 (39.6) |
Hypertension, n (%) | 216 (99.1) | 221 (100.0) |
Diabetes Mellitus, n (%) | 170 (78.0) | 170 (76.9) |
Type 1 | 3 (1.8) | 0 (0.0) |
Type 2 | 167 (98.2) | 170 (100.0) |
Diabetes Mellitus + hypertension | 170 (78.0) | 169 (76.5) |
Hypercholesterolaemia*, n (%) | 212 (97.2) | 213 (96.4) |
Hypertriglyceridaemia**, n (%) | 38 (17.4) | 48 (21.7) |
Chronic kidney disease, n (%) | 30 (13.8) | 21 (9.5) |
Stage of kidney damage, eGFR (mL/min/1,73m2), n (%) | ||
Stage I: > 90 | 0 (0.0) | 1 (4.8) |
Stage II: 60–89 | 1 (3.3) | 0 (0.0) |
Stage III: 45–59 | 29 (96.7) | 20 (95.2) |
Evidence of TOD, n (%) | ||
Subclinical atherosclerosis | 48 (22.0) | 50 (22.6) |
Diabetes Mellitus + albuminuria | 60 (27.5) | 55 (24.9) |
HT + LVH/albuminuria/CKD | 107 (49.1) | 113 (51.1) |
Current medication, n (%) | ||
Taking statins | 218 (100.0) | 221 (100.0) |
Taking ACEi/ARB | 218 (100.0) | 221 (100.0) |
Taking aspirin | 115 (52.8) | 118 (53.4) |
Taking glucose-lowering drugs | 166 (75.1) | 166 (75.1) |